Biotech company Laigo Bio has completed the second close of its seed financing round with an additional $5.5 million bringing the total investment to $17 million.   Laigo will use the seed financing to accelerate the development of its Surface Removal Targeting Chimeras (SureTACs) oncology programmes towards the clinic. It will also advance three candidate programmes for selected autoimmune and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!